<DOC>
	<DOCNO>NCT00469209</DOCNO>
	<brief_summary>Primary Objectives : 1 . To evaluate toxicity safety combination bortezomib arsenic trioxide , ascorbic acid high-dose melphalan patient multiple myeloma 2 . To evaluate efficacy combination bortezomib arsenic trioxide , ascorbic acid high-dose melphalan patient multiple myeloma 3 . To determine effect bortezomib melphalan pharmacokinetics</brief_summary>
	<brief_title>Velcade , Trisenox , Vitamin C Melphalan Myeloma Patients</brief_title>
	<detailed_description>Melphalan design damage DNA cell , may cause cancer cell die . High-dose melphalan consider standard care multiple myeloma . Bortezomib design block protein play role cell function growth , may cause cancer cell die . Arsenic trioxide may cause cancer cell die , researcher want find arsenic trioxide help melphalan kill cancer cell . Vitamin C make arsenic trioxide available inside cancer cell , researcher want learn Vitamin C make arsenic trioxide effective . Before start treatment study , `` screening test . '' These test help doctor decide eligible take part study . You physical exam , include measurement vital sign ( blood pressure , heart rate , temperature , breathe rate ) . Your complete medical history record . You dental exam check infect teeth gum may flare chemotherapy . You bone marrow aspirate biopsy . To collect bone marrow aspirate/biopsy , area hip chest bone numb anesthetic , small amount bone marrow withdrawn large needle . Cytogenetic test perform aspirate sample look genetic abnormality DNA . You x-rays bone take . The study doctor look x-rays see myeloma-related bone change . You also chest x-ray . You blood ( 2 tablespoon ) urine collect routine test . You pulmonary function test , check lung strong enough high-dose chemotherapy . You electrocardiogram ( ECG -- test measure electrical activity heart ) . You also MUGA scan evaluate function heart . Women able child must negative blood pregnancy test . The blood drawn part 2 tablespoon draw screen . If find eligible take part study , randomly assign ( toss dice ) one 3 treatment group . There equal chance assign 3 group . All 3 group receive melphalan , arsenic trioxide , Vitamin C. The second third group also receive bortezomib , different dose level . The first 3 participant assign receive bortezomib study receive low 2 bortezomib dose level . You receive arsenic trioxide needle vein 2 hour , day 7 day ( Days -9 -3 ) . At time , receive Vitamin C day vein 7 day . After receive arsenic trioxide Days -4 -3 , receive melphalan vein 30 minute . If Group 2 3 , receive bortezomib intravenous ( IV ) push Days -9 , -6 , -3 . An IV push take short period time ( le 1 minute ) . You receive standard inpatient outpatient stem cell transplant care test . You sign separate consent form describe transplant procedure risk . Your stem cell reinfused 2 day last dose melphalan . To check side effect , ECG perform 14 day transplant . If intolerable side effect chemotherapy occur sign disease transplant , take study . If already receive melphalan side effect occur , transplant happen . However , intolerable side effect develop melphalan , may take study without transplant . If take study early , still may need return routine post-transplant follow-up visit , transplant physician decides necessary . If sign disease transplant , routine follow-up visit . Blood ( 2 tablespoon ) draw routine test least week first month transplant , every month next 3 month . At 3 , 6 , 12 month transplant , bone marrow biopsy aspirate perform check status disease . You blood ( 2 tablespoon ) urine collect routine test . At 12 month transplant , x-rays bone take . One ( 1 ) year transplant , participation study . This investigational study . Bortezomib , arsenic trioxide , melphalan commercially available FDA-approved use patient myeloma . However , use combination Vitamin C ( also commercially available ) investigational . Up 60 patient take part study . All enrol M. D. Anderson .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Ascorbic Acid</mesh_term>
	<mesh_term>Arsenic trioxide</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>1. ) Primary Refractory Disease ( defined failure achieve even partial response induction therapy ) b ) Consolidation partial remission ( defined decrease continue presence monoclonal protein serum urine immunofixation electrophoresis , and/or presence plasmacytosis bone marrow aspirate biopsy ) c ) Relapsing prior therapy ( disease relapse achieve partial complete response prior conventional highdose therapy ) . 2 . Age 75 year . 3 . Zubrod performance status &lt; 2 . 4 . Left ventricular ejection fraction &gt; 40 % . No uncontrolled arrhythmias symptomatic cardiac disease . 5 . Forced expiratory volume ( FEV1 ) , forced volume vital capacity ( FVC ) Diffusing Capacity Lung Carbon Monoxide ( DLCO ) &gt; 40 % . No symptomatic pulmonary disease . 6 . Serum bilirubin &lt; 2 time upper limit normal , alanine aminotransferase/SGPT &lt; 4 time upper limit normal . No evidence chronic active hepatitis cirrhosis . No effusion ascites &gt; 1L prior drainage . 7 . HIVnegative . 8 . Negative Beta human chorionic gonadotrophin ( hCG ) test woman child bear potential , define postmenopausal 12 month previous surgical sterilization 9 . Patient guardian able sign inform consent 10 . Corrected QT interval le 470 msec . 1 . Corrected QT interval great 470 msec . 2 . Patients complete remission ( define absence monoclonal protein serum urine immunofixation electrophoresis , absence plasmacytosis bone marrow aspirate biopsy ) . 3 . Patients nonsecretory myeloma .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Melphalan</keyword>
	<keyword>Trisenox</keyword>
	<keyword>Arsenic Trioxide</keyword>
	<keyword>Ascorbic Acid</keyword>
	<keyword>Vitamin C</keyword>
	<keyword>Velcade</keyword>
	<keyword>Bortezomib</keyword>
</DOC>